Can a cancer drug tame HHT's dangerous heart and liver complications?
NCT ID NCT07445347
First seen Mar 17, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This study looks at how well and how safely the drug bevacizumab works for people with hereditary hemorrhagic telangiectasia (HHT) who have severe liver issues causing high heart output and possible heart failure. Researchers will check heart function before and after 6 months of treatment using ultrasound or catheterization. About 111 participants from French HHT centers are being invited to join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre hospitalier universitaire de Poitiers
Poitiers, 86000, France
Conditions
Explore the condition pages connected to this study.